United Therapeutics acquiring rival drugmaker

United Therapeutics Corp. has reached a deal to acquire Israel-based SteadyMed Therapeutics Inc. in a deal that's potentially valued at $216 million and that eliminates a serious competitive threat to the Maryland biotech. The Silver Spring drugmaker will acquire SteadyMed for $4.46 per share in cash at closing, already a 68 percent premium on the smaller company's closing price Friday, totaling $141 million. In addition, United Therapeutics has offered another $2.63 per share in cash if SteadyMed's…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news